We concurrently tested the ERK2 inhibitor, no.76 (3-(2-aminoethyl)-5-((4-ethoxyphenyl) methylene)-2,4-thiazolidine-dione, HCl) and found corroborative results showing no impact of ERK on MNK activity in DLBCL (Supplementary Fig. 2). Here, MAPK1 is linked to diffuse large B-cell lymphoma.